Arrowhead to Present at Upcoming Conferences AASLD Annual Meeting 2013 International Meeting on Molecular Biology of Hepatitis B Viruses 2013 Business Wire PASADENA, Calif. -- October 18, 2013 Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on ARC-520, its hepatitis B drug candidate, at two upcoming scientific conferences. Scheduled conference presentations include the following: 2013 International Meeting on Molecular Biology of Hepatitis B Viruses - Shangai, China, October 20-23, 2013 October 23, 2013 – A poster presentation titled, “Kinetics of knockdown from RNAi therapeutic ARC-520 on hepatitis B virus RNA, DNA, S antigen and e antigen in mice and chimpanzee,” will be presented by Christine Wooddell, Ph.D., Senior Scientist; AASLD – The Liver Meeting - Washington, DC, USA, November 1-5, 2013 November 3, 2013 – A poster presentation titled, “ARC-520 RNAi therapeutic reduces HBV DNA, S and e antigen in a chimpanzee,” will be presented by Robert E. Lanford, Ph.D., Texas Biomedical Research Institute. About ARC-520 Approximately 350 million people worldwide are chronically infected with the hepatitis B virus. Chronic HBV infection can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally. Arrowhead’s RNAi-based candidate ARC-520 is designed to treat chronic HBV infection by reducing the expression and release of new viral particles and key viral proteins. The goal is to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without sero-conversion. The siRNAs in ARC-520 intervene at the mRNA level, upstream of where nucleotide and nucleoside analogues act. In transient and transgenic mouse models of HBV infection, a single co-injection of Arrowhead’s DPC delivery vehicle with cholesterol-conjugated siRNA targeting HBV sequences resulted in multi-log knockdown of HBV RNA, proteins and viral DNA with long duration of effect. In a chimpanzee chronically infected with HBV and high viremia and antigenemia, ARC-520 induced rapid reductions of 90-95% in HBV DNA, e-antigen, and s-antigen. Arrowhead has completed enrollment in a phase 1 single ascending dose study in normal volunteers, which the company expects to follow with a phase 2a study in chronic HBV patients. About Arrowhead Research Corporation Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology. For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to firstname.lastname@example.org. Contact: Arrowhead Research Corporation Vince Anzalone, CFA 626-304-3400 or The Trout Group Lauren Glaser 646-378-2972 email@example.com
Arrowhead to Present at Upcoming Conferences
Press spacebar to pause and continue. Press esc to stop.